

# Six-Month Randomized, Multicenter Trial of Closed-Loop

New England Journal of Medicine

381, 1707-1717

DOI: [10.1056/nejmoa1907863](https://doi.org/10.1056/nejmoa1907863)

Citation Report

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Toward Automated Insulin Delivery. <i>New England Journal of Medicine</i> , 2019, 381, 1774-1775.  | 27.0 | 7         |
| 2  | Carbohydrate Intake in the Context of Exercise in People with Type 1 Diabetes. <i>Nutrients</i> , 2019, 11, 3017.  | 4.1  | 20        |
| 3  | Nonadjunctive Use of Continuous Glucose Monitoring: The End of Fingersticks?. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 67-68.   | 4.4  | 5         |
| 4  | Who Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 404-410.  | 4.4  | 14        |
| 5  | Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2020, 95, 15-21.   | 3.0  | 1         |
| 7  | Automation and interoperability of a nurse-managed insulin infusion protocol as a model to improve safety and efficiency in the delivery of high-alert medications. <i>Journal of Patient Safety and Risk Management</i> , 2020, 25, 5-14.             | 0.6  | 4         |
| 8  | In Silico Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 112-120.   | 4.4  | 32        |
| 9  | Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?. <i>Frontiers in Endocrinology</i> , 2020, 11, 609.   | 3.5  | 25        |
| 10 | In-Silico Evaluation of Glucose Regulation Using Policy Gradient Reinforcement Learning for Patients with Type 1 Diabetes Mellitus. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6350.  | 2.5  | 8         |
| 11 | Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 3024-3033.                                  | 8.6  | 85        |
| 12 | Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108502.  | 2.8  | 52        |
| 14 | KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.   | 5.2  | 692       |
| 15 | The trials and tribulations of determining HbA1c targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 717-730.   | 9.6  | 39        |
| 16 | User and Healthcare Professional Perspectives on Do-It-Yourself Artificial Pancreas Systems: A Need for Guidelines. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 224-227.   | 2.2  | 9         |
| 17 | Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882095014. | 3.2  | 40        |
| 18 | Current State and Evidence of Cellular Encapsulation Strategies in Type 1 Diabetes. , 2020, 10, 839-878.   |      | 19        |
| 19 | Training and Support for Hybrid Closed-Loop Therapy. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 218-223.  | 2.2  | 21        |
| 20 | A novel cellular engineering approach to diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 477-478.   | 9.6  | 1         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 21 | The artificial pancreas. <i>Current Opinion in Organ Transplantation</i> , 2020, Publish Ahead of Print, 336-342.  | 1.6  | 22        |
| 22 | Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2960-e2969.   | 3.6  | 99        |
| 25 | Designing a bioelectronic treatment for Type 1 diabetes: targeted parasympathetic modulation of insulin secretion. <i>Bioelectronics in Medicine</i> , 2020, 3, 17-31.   | 2.0  | 7         |
| 26 | Smarter Modeling to Enable a Smarter Insulin. <i>Diabetes</i> , 2020, 69, 1608-1610.   | 0.6  | 8         |
| 27 | Insulin-delivery methods for children and adolescents with type 1 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882090601.   | 3.2  | 4         |
| 28 | Improving Clinical Outcomes in Newly Diagnosed Pediatric Type 1 Diabetes: Teamwork, Targets, Technology, and Tight Control—The 4T Study. <i>Frontiers in Endocrinology</i> , 2020, 11, 360.  | 3.5  | 39        |
| 29 | The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis. <i>Pediatric Diabetes</i> , 2020, 21, 1256-1267.  | 2.9  | 14        |
| 30 | Review of the Omnipod <sup>®</sup> 5 Automated Glucose Control System Powered by Horizon <sup>®</sup> , <sup>†</sup> for the treatment of Type 1 diabetes. <i>Therapeutic Delivery</i> , 2020, 11, 507-519.  | 2.2  | 23        |
| 31 | New and Emerging Technologies in Type 1 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 667-678.  | 3.2  | 24        |
| 32 | Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 373-382.  | 2.2  | 15        |
| 33 | A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 836-845.   | 27.0 | 271       |
| 34 | A clinical review of the t:slim X2 insulin pump. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1675-1687.   | 5.0  | 19        |
| 35 | Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2020, 20, 52.   | 4.2  | 7         |
| 36 | More Focus Is Needed to Reduce Adverse Events for Diabetes Devices. <i>Journal of Diabetes Science and Technology</i> , 2020, , 193229682095162.   | 2.2  | 3         |
| 37 | An Adhesive Hydrogel with a Co-Load Sharing Effect as Tissue Bandages for Drug and Cell Delivery. <i>Advanced Materials</i> , 2020, 32, e2001628.  | 21.0 | 128       |
| 38 | Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 2721-2729. | 8.6  | 32        |
| 39 | 3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes. <i>Tissue Engineering - Part B: Reviews</i> , 2021, 27, 238-252.  | 4.8  | 11        |
| 40 | The Potential Role of Sensors, Wearables and Telehealth in the Remote Management of Diabetes-Related Foot Disease. <i>Sensors</i> , 2020, 20, 4527.  | 3.8  | 32        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 43 | Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. <i>Diabetes Therapy</i> , 2020, 11, 1251-1269.   | 2.5  | 109       |
| 44 | Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 812-821.                                    | 4.4  | 19        |
| 45 | Closed-loop bioelectronic medicine for diabetes management. <i>Bioelectronic Medicine</i> , 2020, 6, 11.   | 2.3  | 18        |
| 46 | The closed-loop artificial pancreas in 2020. <i>Artificial Organs</i> , 2020, 44, 671-679.   | 1.9  | 16        |
| 47 | The Evolution of Insulin and How it Informs Therapy and Treatment Choices. <i>Endocrine Reviews</i> , 2020, 41, 733-755.   | 20.1 | 116       |
| 48 | Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 1822-1828.   | 8.6  | 34        |
| 49 | Safety and Functional Integrity of Continuous Glucose Monitoring Components After Simulated Radiologic Procedures. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682092094.  | 2.2  | 24        |
| 50 | Feature-Based Machine Learning Model for Real-Time Hypoglycemia Prediction. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682092262.   | 2.2  | 58        |
| 51 | Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. <i>Endocrine Reviews</i> , 2020, 41, 756-774.   | 20.1 | 77        |
| 52 | Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 501-508.  | 4.4  | 35        |
| 53 | The Use of Technology in Managing Diabetes in Youth Part 2—Insulin Pump Technologies: Information and Tips for the School Nurse. <i>NASN School Nurse (Print)</i> , 2020, 35, 188-195.   | 0.7  | 4         |
| 54 | Artificial Intelligence in Decision Support Systems for Type 1 Diabetes. <i>Sensors</i> , 2020, 20, 3214.  | 3.8  | 47        |
| 56 | Artificial Intelligence and Machine Learning Applied at the Point of Care. <i>Frontiers in Pharmacology</i> , 2020, 11, 759.   | 3.5  | 35        |
| 58 | Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update. <i>Endocrine Practice</i> , 2020, 26, 714-721.   | 2.1  | 14        |
| 59 | Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 448-458.   | 7.1  | 36        |
| 60 | Update: Pediatric Diabetes. <i>Journal of Diabetes</i> , 2020, 12, 769-771.  | 1.8  | 0         |
| 61 | Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 594-601.   | 4.4  | 18        |
| 62 | The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). <i>Diabetes Care</i> , 2020, 43, 2017-2024. | 8.6  | 34        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 63 | CREATE (Community deRivEd AutomATEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetes. Journal of Diabetes and Metabolic Disorders, 2020, 19, 1615-1629. | 1.9  | 29        |
| 64 | Customized treatment for Type 1 diabetes patients using novel software. Journal of Clinical and Translational Endocrinology: Case Reports, 2020, 16, 100057.  | 0.6  | 1         |
| 65 | Emerging routes to the generation of functional $\beta$ -cells for diabetes mellitus cell therapy. Nature Reviews Endocrinology, 2020, 16, 506-518.   | 9.6  | 85        |
| 66 | Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy. Expert Review of Medical Devices, 2020, 17, 707-720.  | 2.8  | 52        |
| 67 | Clinical impact of CGM use. , 2020, , 135-158.  |      | 0         |
| 68 | CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes. Expert Opinion on Investigational Drugs, 2020, 29, 221-236.  | 4.1  | 27        |
| 69 | Decision Support Systems and Closed Loop. Diabetes Technology and Therapeutics, 2020, 22, S-47-S-62.  | 4.4  | 2         |
| 70 | Use of Diabetes Technology in Children. Endocrinology and Metabolism Clinics of North America, 2020, 49, 19-35.   | 3.2  | 16        |
| 71 | Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes. Expert Opinion on Drug Delivery, 2020, 17, 157-166.  | 5.0  | 11        |
| 72 | Where Do We Stand with Closed-Loop Systems and Their Challenges?. Diabetes Technology and Therapeutics, 2020, 22, 485-491.  | 4.4  | 4         |
| 73 | Clinical use of a 180 $\mu$ g/day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1056-1061.   | 4.4  | 17        |
| 74 | Reflections on Diabetes Care at the End of the Second Decade of the 21st Century. Diabetes Technology and Therapeutics, 2020, 22, 63-65.  | 4.4  | 2         |
| 75 | Closed-loop insulin delivery: understanding when and how it is effective. The Lancet Digital Health, 2020, 2, e50-e51.  | 12.3 | 4         |
| 76 | Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 577-578.   | 27.0 | 2         |
| 77 | Monitoring of Pediatric Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 128.   | 3.5  | 25        |
| 79 | Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. The Lancet Digital Health, 2020, 2, e64-e73.  | 12.3 | 34        |
| 80 | Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care, 2020, 43, 607-615.  | 8.6  | 40        |
| 81 | Diabetes and Technology in the Covid-19 Pandemic Crisis. Journal of Diabetes Science and Technology, 2021, 15, 377-378.   | 2.2  | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 82 | Practical implementation of automated closed-loop insulin delivery: A French position statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101206.   | 2.9 | 19        |
| 83 | Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 245-252.  | 4.4 | 13        |
| 84 | Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 168-174.   | 4.4 | 9         |
| 85 | Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 384-391.   | 4.4 | 37        |
| 86 | Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 342-349.   | 4.4 | 58        |
| 87 | Standardized Hybrid Closed-Loop System Reporting. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 323-331.  | 4.4 | 10        |
| 88 | Hybrid closed-loop therapy: Where are we in 2021?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 655-660.   | 4.4 | 88        |
| 89 | Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The <sc>DAPADream</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 599-608.  | 4.4 | 36        |
| 90 | Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. <i>Diabetes Care</i> , 2021, 44, 141-149.   | 8.6 | 19        |
| 91 | A review of biomarkers in the context of type 1 diabetes: Biological sensing for enhanced glucose control. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10201.  | 7.1 | 33        |
| 92 | A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 367-375.  | 4.4 | 80        |
| 93 | The majority of people with type <sc>1</sc> diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the <sc>GOLD</sc> randomized trial (<sc>GOLDâ€5</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 619-630. | 4.4 | 9         |
| 94 | Sleep and <sc>diabetesâ€specific psychoâ€behavioral</sc> outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. <i>Pediatric Diabetes</i> , 2021, 22, 495-502.   | 2.9 | 28        |
| 95 | A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. <i>Endocrine Practice</i> , 2021, 27, 545-551.   | 2.1 | 5         |
| 96 | Anticipation of Historical Exercise Patterns by a Novel Artificial Pancreas System Reduces Hypoglycemia During and After Moderate-Intensity Physical Activity in People with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 277-285.                        | 4.4 | 23        |
| 97 | 9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetesâ€2021</i>. <i>Diabetes Care</i> , 2021, 44, S111-S124.  | 8.6 | 787       |
| 98 | Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 460-466.   | 4.4 | 7         |
| 99 | First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 410-424.   | 4.4 | 52        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 100 | Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review. <i>Acta Diabetologica</i> , 2021, 58, 539-547.   | 2.5  | 25        |
| 101 | Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 187-194.  | 4.4  | 6         |
| 102 | A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison. <i>Diabetes Care</i> , 2021, 44, 133-140.   | 8.6  | 162       |
| 103 | The Digital/Virtual Diabetes Clinic: The Future Is Now—Recommendations from an International Panel on Diabetes Digital Technologies Introduction. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 146-154. | 4.4  | 79        |
| 104 | Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 120-127.   | 4.4  | 89        |
| 105 | Latest Advancements in Artificial Intelligence-Enabled Technologies in Treating Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 195-197.  | 2.2  | 2         |
| 106 | A demanding path from iPSCs toward pancreatic $\beta$ - and $\alpha$ -cells. , 2021, , 227-256.  |      | 0         |
| 107 | Point of care TECHNOLOGIES. , 2021, , 73-84.   |      | 0         |
| 108 | Automatic Regulation of Basal Insulin Infusion in a Personalized Insulin Therapy System. <i>Bio-Medical Engineering</i> , 2021, 54, 366-370.   | 0.5  | 2         |
| 109 | Artificial pancreas. , 2021, , 503-537.  |      | 2         |
| 110 | Endocrine Disorders in Infants, Children, and Adolescents. , 2021, , .   |      | 0         |
| 111 | In Silico Testing of a Control Algorithm for a Personalized Insulin Therapy System. , 2021, , .  |      | 1         |
| 112 | A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. <i>Lancet, The</i> , 2021, 397, 208-219.                  | 13.7 | 206       |
| 113 | Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. <i>Journal of Clinical Investigation</i> , 2021, 131, .   | 8.2  | 35        |
| 114 | A Data-Driven Approach to Classifying Daily Continuous Glucose Monitoring (CGM) Time Series. <i>IEEE Transactions on Biomedical Engineering</i> , 2022, 69, 654-665.   | 4.2  | 15        |
| 115 | AIM in Endocrinology. , 2021, , 1-17.  |      | 0         |
| 116 | Time in range centered diabetes care. <i>Clinical Pediatric Endocrinology</i> , 2021, 30, 1-10.  | 0.8  | 28        |
| 117 | Closed-Loop Control for Fluid Resuscitation: Recent Advances and Future Challenges. <i>Frontiers in Veterinary Science</i> , 2021, 8, 642440.  | 2.2  | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 118 | New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 47-59.   | 0.2 | 0         |
| 119 | Predictive Low-Glucose Suspend Necessitates Less Carbohydrate Supplementation to Rescue Hypoglycemia: Need to Revisit Current Hypoglycemia Treatment Guidelines. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 512-516.  | 4.4 | 12        |
| 120 | Technologies in the management of type 1 diabetes. <i>Medical Journal of Australia</i> , 2021, 214, 202.   | 1.7 | 1         |
| 121 | Pre- and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis. <i>Pediatric Diabetes</i> , 2021, 22, 594-604.   | 2.9 | 33        |
| 122 | Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAPO2 study): an open-label, multicentre, multinational, randomised cross-over study protocol. <i>BMJ Open</i> , 2021, 11, e042790. | 1.9 | 10        |
| 123 | New closed-loop insulin systems. <i>Diabetologia</i> , 2021, 64, 1007-1015.  | 6.3 | 146       |
| 124 | Characterizing Glycemic Control and Sleep in Adults with Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.   | 2.3 | 8         |
| 125 | Ready or not? Greater readiness for independent self-care predicts better self-management but not HbA1c in teens with type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14507.  | 2.3 | 8         |
| 126 | Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 969-975.                       | 8.6 | 158       |
| 127 | Stem Cell-Based Clinical Trials for Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2021, 12, 631463.   | 3.5 | 58        |
| 128 | Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1272-1281.                      | 4.4 | 19        |
| 129 | Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. <i>Endocrinology and Metabolism</i> , 2021, 36, 41-50.  | 3.0 | 4         |
| 130 | Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 508-511.  | 4.4 | 11        |
| 131 | Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use. <i>Canadian Journal of Diabetes</i> , 2021, 45, 750-756.e3.  | 0.8 | 8         |
| 133 | Long-term use of the hybrid artificial pancreas by adjusting carbohydrate ratios and programmed basal rate: A reinforcement learning approach. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 200, 105936.  | 4.7 | 14        |
| 134 | Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 622901.  | 3.5 | 16        |
| 135 | Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-35-S-39.  | 4.4 | 34        |
| 136 | Características clínicas y manejo de la diabetes tipo 1 en España. Estudio SED1. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 642-653.  | 0.3 | 14        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 137 | Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2805.  | 4.1  | 8         |
| 138 | Using digital twins in viral infection. <i>Science</i> , 2021, 371, 1105-1106.   | 12.6 | 73        |
| 139 | Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 217-240.   | 5.7  | 19        |
| 140 | Predictors of Time-in-Range (70â€“180â€“mg/dL) Achieved Using a Closed-Loop Control System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 475-481.   | 4.4  | 36        |
| 141 | Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1571-1579. | 4.4  | 5         |
| 142 | Selectivity and Sensitivity of Near-Infrared Spectroscopic Sensing of Î²-Hydroxybutyrate, Glucose, and Urea in Ternary Aqueous Solutions. <i>Analytical Chemistry</i> , 2021, 93, 5586-5595.   | 6.5  | 1         |
| 143 | Diabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization. <i>Journal of Medical Internet Research</i> , 2021, 23, e23475.   | 4.3  | 9         |
| 144 | Hybrid closedâ€“loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A doubleâ€“blind, multicentre, multinational, randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1389-1396.                    | 4.4  | 58        |
| 145 | Wearable Glucose Monitoring and Implantable Drug Delivery Systems for Diabetes Management. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100194.  | 7.6  | 38        |
| 146 | Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 268-276.   | 4.4  | 16        |
| 147 | Insulin pump therapy. <i>Paediatrics and Child Health (United Kingdom)</i> , 2021, 31, 129-140.  | 0.4  | 1         |
| 148 | Cost considerations for adoption of diabetes technology are pervasive: A qualitative study of persons living with type 1 diabetes and their families. <i>Diabetic Medicine</i> , 2021, 38, e14575.   | 2.3  | 16        |
| 149 | A Modified CGM Algorithm Enhances Data Availability While Retaining iCGM Performance. <i>Journal of Diabetes Science and Technology</i> , 2021, , 193229682110075.   | 2.2  | 1         |
| 150 | Benefits and Challenges of Current Closed-Loop Technologies in Children and Young People With Type 1 Diabetes. <i>Frontiers in Pediatrics</i> , 2021, 9, 679484.   | 1.9  | 29        |
| 151 | Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes. <i>World Journal of Diabetes</i> , 2021, 12, 306-330.  | 3.5  | 2         |
| 152 | Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 304-317.   | 11.4 | 18        |
| 153 | User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. <i>Diabetes Care</i> , 2021, 44, e148-e150.   | 8.6  | 12        |
| 154 | Artificial Pancreas: <i>In Silico</i> Study Shows No Need of Meal Announcement and Improved Time in Range of Glucose With Intraperitoneal vs. Subcutaneous Insulin Delivery. <i>IEEE Transactions on Medical Robotics and Bionics</i> , 2021, 3, 306-314.  | 3.2  | 15        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 155 | Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards. <i>Diabetes Care</i> , 2021, 44, e121-e123.  | 8.6  | 40        |
| 156 | Outcomes for continuous subcutaneous insulin infusion users in young adults from lower socioeconomic backgrounds. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00252.  | 2.4  | 1         |
| 157 | Algorithms for Automated Insulin Delivery: An Overview. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 1228-1238.  | 2.2  | 8         |
| 158 | Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials. <i>Journal of Diabetes Science and Technology</i> , 2021, , 193229682110152.                               | 2.2  | 7         |
| 159 | Response to Comment on "One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology" by Goran Petrovski et al.. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 729-729.                                       | 4.4  | 0         |
| 160 | MiniMed <sup>TM</sup> 780G Insulin Pump System with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy. <i>Expert Review of Medical Devices</i> , 2021, 18, 499-504.                         | 2.8  | 18        |
| 161 | Associations of Time in Range and Other Continuous Glucose Monitoring "Derived Metrics With Well-Being and Patient-Reported Outcomes: Overview and Trends. <i>Diabetes Spectrum</i> , 2021, 34, 149-155.                                    | 1.0  | 9         |
| 162 | Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 401-409.  | 4.4  | 27        |
| 163 | Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2048-2057. | 4.4  | 28        |
| 164 | Diabetes Technology and Therapy in the Pediatric Age Group. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-113-S-130.  | 4.4  | 0         |
| 165 | Candidate Selection for Hybrid Closed Loop Systems. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 760-762.  | 4.4  | 9         |
| 166 | Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 715-725.   | 4.4  | 7         |
| 167 | Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 673-683.  | 4.4  | 30        |
| 168 | L'insulinothérapie au xxi <sup>e</sup> siècle : une symphonie de plus en plus harmonieuse. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 3S53-3S63.   | 0.1  | 0         |
| 169 | A Fully Integrated Closed-Loop System Based on Mesoporous Microneedles-Iontophoresis for Diabetes Treatment. <i>Advanced Science</i> , 2021, 8, e2100827.   | 11.2 | 91        |
| 170 | Weekly Insulin Becoming a Reality. <i>Diabetes Care</i> , 2021, 44, 1459-1461.  | 8.6  | 5         |
| 171 | Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 837-843.  | 4.4  | 43        |
| 172 | Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes: consensus statement of the ADS/ADEA/APEG/ADIPS Working Group. <i>Medical Journal of Australia</i> , 2021, 215, 473-478.              | 1.7  | 10        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 173 | American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. <i>Endocrine Practice</i> , 2021, 27, 505-537.                      | 2.1  | 135       |
| 174 | Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1630-1640.                 | 8.6  | 133       |
| 175 | La presencia de complicaciones microvasculares se asocia con un mal control metabólico evolutivo en pacientes con diabetes tipo 1. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 389-397.                                 | 0.3  | 5         |
| 176 | A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 467-470.   | 4.4  | 11        |
| 178 | Optimizing antimicrobial use: challenges, advances and opportunities. <i>Nature Reviews Microbiology</i> , 2021, 19, 747-758.   | 28.6 | 51        |
| 179 | Smart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes. <i>Nature Communications</i> , 2021, 12, 3388.  | 12.8 | 29        |
| 180 | Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. <i>Artificial Organs</i> , 2021, 45, 968-986.  | 1.9  | 24        |
| 181 | Adolescents'™ Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1042-1051. | 2.2  | 9         |
| 182 | Closed-loop technology: a practical guide. <i>Practical Diabetes</i> , 2021, 38, 33-39.   | 0.3  | 10        |
| 183 | Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. <i>Science</i> , 2021, 373, 522-527.  | 12.6 | 43        |
| 184 | Heterogeneity of Access to Diabetes Technology Depending on Area Deprivation and Demographics Between 2016 and 2019 in Germany. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1059-1068.                            | 2.2  | 18        |
| 185 | Pivotal trial of the Omnipod 5 Automated Insulin Delivery System shows promising results. <i>Artificial Organs</i> , 2021, 45, 956-957.   | 1.9  | 0         |
| 186 | Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682110299.   | 2.2  | 3         |
| 187 | Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes. , 2021, 38, S4-S8.   |      | 0         |
| 188 | Efficacy of advanced hybrid closed loop systems for the management of type 1 diabetes in children. <i>Minerva Pediatrics</i> , 2022, 73, .  | 0.4  | 9         |
| 189 | Smartphone-Flashlight-Mediated Remote Control of Rapid Insulin Secretion Restores Glucose Homeostasis in Experimental Type 1 Diabetes. <i>Small</i> , 2021, 17, e2101939.   | 10.0 | 18        |
| 191 | Multi-Clinic Quality Improvement Initiative Increases Continuous Glucose Monitoring Use Among Adolescents and Young Adults With Type 1 Diabetes. <i>Clinical Diabetes</i> , 2021, 39, 264-271.                                      | 2.2  | 30        |
| 192 | Diabetes Technology Meeting 2020. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 916-960.  | 2.2  | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 193 | Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 828-836.  | 4.4 | 21        |
| 194 | Dynamic Insulin Basal Needs Estimation and Parameters Adjustment in Type 1 Diabetes. <i>Sensors</i> , 2021, 21, 5226.   | 3.8 | 1         |
| 195 | Aplicación de las novedades de los Standards of Medical Care in Diabetes ADA 2021 a la práctica clínica en nuestro país. Documento SED-SEEN. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 664-664.                               | 0.3 | 0         |
| 196 | Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?. <i>Biomolecules</i> , 2021, 11, 1281.   | 4.0 | 5         |
| 197 | Advanced Closed-Loop Control System Improves Postprandial Glycemic Control Compared With a Hybrid Closed-Loop System Following Unannounced Meal. <i>Diabetes Care</i> , 2021, 44, 2379-2387.  | 8.6 | 22        |
| 198 | Disparities in Utilization and Outcomes With Continuous Subcutaneous Insulin Infusion in Young Adults With Type 1 Diabetes. <i>Endocrine Practice</i> , 2021, 27, 769-775.  | 2.1 | 1         |
| 199 | Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventions. <i>PLoS Computational Biology</i> , 2021, 17, e1009303.   | 3.2 | 8         |
| 200 | Youth and parent preferences for an ideal <sc>AP</sc> system: It is all about reducing burden. <i>Pediatric Diabetes</i> , 2021, 22, 1063-1070.   | 2.9 | 8         |
| 201 | Newest Diabetes-Related Technologies for Pediatric Type 1 Diabetes and Its Impact on Routine Care: a Narrative Synthesis of the Literature. <i>Current Pediatrics Reports</i> , 2021, , 1-12.   | 4.0 | 3         |
| 202 | Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real-life study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2484-2491. | 4.4 | 18        |
| 203 | Vomiting and hyperkalemia are novel clues for emergency room diagnosis of type 1 diabetic ketoacidosis: a retrospective comparison between diabetes types. <i>Diabetology International</i> , 2022, 13, 272-279.                            | 1.4 | 0         |
| 204 | Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations. <i>Current Opinion in Biomedical Engineering</i> , 2021, 19, 100312.  | 3.4 | 19        |
| 205 | Automated insulin dosing systems: Advances after a century of insulin. <i>Diabetic Medicine</i> , 2021, 38, e14695.   | 2.3 | 4         |
| 206 | The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.                       | 8.6 | 244       |
| 207 | Diabetes Technology Use in Remote Pediatric Patients with Type 1 Diabetes Using Clinic-to-Clinic Telemedicine. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 67-74.   | 4.4 | 5         |
| 208 | Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1232-1242.   | 2.2 | 7         |
| 209 | A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 629-640.  | 4.7 | 13        |
| 210 | The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.                        | 6.3 | 128       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 211 | Incorporating Glucose Variability into Glucose Forecasting Accuracy Assessment Using the New Glucose Variability Impact Index and the Prediction Consistency Index: An LSTM Case Example. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 7-18.       | 2.2  | 12        |
| 212 | Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-28-S-35.  | 4.4  | 2         |
| 213 | Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-5-S-11.   | 4.4  | 26        |
| 214 | A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. <i>The Lancet Digital Health</i> , 2021, 3, e723-e732.                                   | 12.3 | 21        |
| 215 | Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 281-293.   | 2.4  | 7         |
| 216 | One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 601-608.  | 4.4  | 135       |
| 217 | Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells. <i>Protein and Cell</i> , 2022, 13, 476-489.  | 11.0 | 23        |
| 219 | Graph Representation Forecasting of Patient's Medical Conditions: Toward a Digital Twin. <i>Frontiers in Genetics</i> , 2021, 12, 652907.   | 2.3  | 20        |
| 220 | Real-World Performance of the MiniMed 780G System: First Report of Outcomes from 4120 Users. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 113-119.   | 4.4  | 110       |
| 221 | Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 791-798.   | 4.4  | 13        |
| 222 | Advanced hybrid artificial pancreas system improves on unannounced meal response - In silico comparison to currently available system. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 211, 106401.   | 4.7  | 20        |
| 223 | Efficacy of Hybrid Closed-Loop Insulin Delivery System in a Hospital Setting: A Case Series. <i>AACE Clinical Case Reports</i> , 2021, 7, 184-188.  | 1.1  | 6         |
| 224 | Cambridge Hybrid Closed-Loop Algorithm in Children and Adolescents with Type 1 Diabetes: A Multicentre 6-Month Randomised Trial. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 0         |
| 225 | Artificial Pancreas Technology Offers Hope for Childhood Diabetes. <i>Current Nutrition Reports</i> , 2021, 10, 47-57.  | 4.3  | 8         |
| 226 | Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial. <i>Diabetes Care</i> , 2021, 44, 836-838.   | 8.6  | 44        |
| 227 | Impact of glucagon response on early postprandial glucose excursions irrespective of residual $\beta$ -cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1367-1376. | 2.4  | 9         |
| 228 | The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. <i>Diabetes Care</i> , 2021, 44, 301-312.  | 8.6  | 32        |
| 229 | The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 663-669.                       | 2.2  | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 230 | Updates on Technology for Diabetes Mellitus. Current Emergency and Hospital Medicine Reports, 2020, 8, 35-39.   | 1.5 | 1         |
| 232 | Certified Interoperability Allows a More Secure Move to the Artificial Pancreas Through a New Concept: "Make-It-Yourself". Journal of Diabetes Science and Technology, 2020, 14, 195-197.                               | 2.2 | 2         |
| 233 | Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 865-872.  | 0.9 | 4         |
| 234 | Automated Insulin Delivery: Easy Enough to Use in Primary Care?. Clinical Diabetes, 2020, 38, 474-485.  | 2.2 | 13        |
| 235 | Lower Daily Carbohydrate Intake Is Associated With Improved Glycemic Control in Adults With Type 1 Diabetes Using a Hybrid Closed-Loop System. Diabetes Care, 2020, 43, 3102-3105.                                      | 8.6 | 11        |
| 236 | Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care, 2021, 44, 473-478.   | 8.6 | 28        |
| 237 | 7. Diabetes Technology: <i>Standards of Medical Care in Diabetesâ€”2021</i>. Diabetes Care, 2021, 44, S85-S99.  | 8.6 | 173       |
| 238 | 13. Children and Adolescents: <i>Standards of Medical Care in Diabetesâ€”2021</i>. Diabetes Care, 2021, 44, S180-S199.  | 8.6 | 160       |
| 239 | New technical approach to the diabetes therapy. Minerva Pediatrica, 2020, 72, 263-277.  | 2.7 | 3         |
| 240 | Accuracy of the Dexcom G6 Glucose Sensor during Aerobic, Resistance, and Interval Exercise in Adults with Type 1 Diabetes. Biosensors, 2020, 10, 138.   | 4.7 | 23        |
| 241 | Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data. Diabetes Technology and Therapeutics, 2022, 24, 140-142.   | 4.4 | 11        |
| 242 | Safety and Glycemic Outcomes During the MiniMedâ„¢ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 178-189.            | 4.4 | 107       |
| 243 | The automated pancreas: A review of technologies and clinical practice. Diabetes, Obesity and Metabolism, 2022, 24, 43-57.  | 4.4 | 13        |
| 244 | Charting the next century of insulin replacement with cell and gene therapies. Med, 2021, 2, 1138-1162.   | 4.4 | 3         |
| 245 | The presence of microvascular complications is associated with a poor evolution of metabolic control in patients with type 1 diabetes mellitus. EndocrinologÃ­a Diabetes Y NutriciÃ³n (English Ed ), 2021, 68, 389-397. | 0.2 | 0         |
| 246 | Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.   | 6.2 | 54        |
| 247 | Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study. Journal of Diabetes Science and Technology, 2023, 17, 176-185.                   | 2.2 | 6         |
| 248 | Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.   | 2.5 | 3         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 249 | Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. <i>Clinical Diabetes</i> , 2022, 40, 168-184.  | 2.2  | 10        |
| 250 | Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. <i>Diabetes Therapy</i> , 2021, 12, 3107-3135.  | 2.5  | 16        |
| 252 | The Present and Future of Continuous Glucose Monitoring. <i>Journal of Korean Diabetes</i> , 2020, 21, 179-183.   | 0.3  | 2         |
| 253 | Miscellaneous Areas of Personalized Medicine. , 2021, , 375-402.  |      | 0         |
| 254 | Randomized Crossover Comparison of Automated Insulin Delivery Versus Conventional Therapy Using an Unlocked Smartphone with Scheduled Pasta and Rice Meal Challenges in the Outpatient Setting. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 865-874.        | 4.4  | 8         |
| 255 | Glucose Control in the Intensive Care Unit. , 2020, , 579-589.  |      | 0         |
| 258 | Opportunities and challenges in closed-loop systems in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 6-8.   | 11.4 | 14        |
| 259 | ROLE OF ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT. <i>International Journal of Engineering Technologies and Management Research</i> , 2020, 7, 80-88.  | 0.1  | 0         |
| 261 | The Evolution of Insulin Administration in Type 1 Diabetes. <i>Journal of Diabetes Mellitus</i> , 2021, 11, 249-277.  | 0.3  | 0         |
| 262 | Practical implementation of remote continuous glucose monitoring in hospitalized patients with diabetes. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 452-458.   | 1.0  | 9         |
| 263 | Barriers to Uptake of Insulin Technologies and Novel Solutions. <i>Medical Devices: Evidence and Research</i> , 2021, Volume 14, 339-354.   | 0.8  | 10        |
| 264 | Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 58-74.   | 11.4 | 61        |
| 265 | Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 813-839.   | 4.7  | 34        |
| 266 | Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. <i>Diabetes Care</i> , 2022, 45, 381-390.  | 8.6  | 43        |
| 268 | Application of the changes in the Standards of Medical Care in Diabetes ADA 2021 to clinical practice in our country. SED-SEEN document. <i>Endocrinología y Nutrición (English Ed)</i> , 2021, 68, 664-667.  | 0.2  | 0         |
| 269 | Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 511-521.                | 4.4  | 12        |
| 270 | Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 157-166. | 4.4  | 7         |
| 271 | Clinical characteristics and management of type 1 diabetes in Spain. The SED1 study. <i>Endocrinología y Nutrición (English Ed)</i> , 2021, 68, 642-653.  | 0.2  | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 272 | Using an Online Disturbance Rejection and Anticipation System to Reduce Hyperglycemia in a Fully Closed-Loop Artificial Pancreas System. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 52-60.   | 2.2 | 7         |
| 273 | Towards a Rational Balanced Pancreatic and Islet Allocation Schema. <i>Cell Transplantation</i> , 2021, 30, 096368972110571.  | 2.5 | 2         |
| 274 | Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 58-62.  | 4.4 | 0         |
| 275 | Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies. <i>Diabetes Care</i> , 2022, 45, 520-528.  | 8.6 | 21        |
| 276 | Recent advances in closed-loop insulin delivery. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154953.  | 3.4 | 16        |
| 277 | Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems. <i>Journal of Clinical and Translational Endocrinology</i> , 2022, 27, 100282.  | 1.4 | 5         |
| 278 | A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 802419.   | 3.5 | 18        |
| 279 | The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 446-452.  | 4.4 | 14        |
| 280 | Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 588-591.  | 4.4 | 23        |
| 281 | Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 338-349.   | 4.4 | 2         |
| 282 | Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed 670G system trial. <i>Pediatric Diabetes</i> , 2022, 23, 324-329.  | 2.9 | 41        |
| 283 | Current Status and Emerging Options for Automated Insulin Delivery Systems. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 362-371.  | 4.4 | 31        |
| 284 | Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 592-597.  | 4.4 | 2         |
| 285 | Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 357-361.   | 4.4 | 7         |
| 287 | Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 409-415.   | 4.4 | 14        |
| 288 | The beneficial effects of closed-loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU-WP10 trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 956-961. | 4.4 | 5         |
| 289 | Optimized adaptive tree seed Kalman filter for a diabetes recommendation system's bilevel performance improvement strategy for healthcare applications. , 2022, , 191-202.  |     | 31        |
| 291 | A practical approach to continuous glucose monitoring (rtCGM) and FreeStyle Libre systems (isCGM) in children and young people with Type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109196.  | 2.8 | 8         |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 292 | Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale. <i>BMJ Open</i> , 2022, 12, e050635.  | 1.9  | 5         |
| 293 | Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 396-402.             | 4.4  | 16        |
| 294 | Further perspectives and challenges. , 2022, , 231-279.   |      | 0         |
| 295 | An Opportunity for Improvement: Evaluation of Diabetes Technology Education Among Adult Endocrinology Training Programs. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210771.   | 2.2  | 1         |
| 296 | Delivering evidence-based interventions for type 1 diabetes in the virtual world – A review of UK practice during the SARS-CoV-2 pandemic. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109777.  | 2.8  | 1         |
| 297 | Quantifying the impact of physical activity on future glucose trends using machine learning. <i>IScience</i> , 2022, 25, 103888.  | 4.1  | 16        |
| 298 | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2022. <i>Diabetes Care</i> , 2022, 45, S125-S143.  | 8.6  | 534       |
| 299 | AIM in Endocrinology. , 2022, , 673-688.  |      | 0         |
| 300 | Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2022, 37, 26-37.  | 3.0  | 20        |
| 301 | Evaluation of a New Clinical Tool to Enhance Clinical Care of Control-IQ Users. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210818.  | 2.2  | 0         |
| 302 | Telehealth Technologies and Their Benefits to People With Diabetes. <i>Diabetes Spectrum</i> , 2022, 35, 8-15.  | 1.0  | 2         |
| 303 | Hypoglycemia in Prospective Multi-Center Study of Pregnancies with Pre-existing Type 1 Diabetes on Sensor Augmented Pump Therapy: The LOIS-P Study. <i>Diabetes Technology and Therapeutics</i> , 2022, , .   | 4.4  | 1         |
| 304 | Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial. <i>The Lancet Digital Health</i> , 2022, 4, e158-e168.                             | 12.3 | 16        |
| 305 | Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e135-e142. | 4.6  | 38        |
| 306 | Zone-MPC Automated Insulin Delivery Algorithm Tuned for Pregnancy Complicated by Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 768639.   | 3.5  | 7         |
| 307 | Switching from predictive low glucose suspend to advanced hybrid closed loop control: Effects on glucose control and patient reported outcomes. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109784.                                   | 2.8  | 12        |
| 308 | A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.  | 2.2  | 69        |
| 309 | Management of Type 1 Diabetes in Children in the Outpatient Setting. <i>Pediatrics in Review</i> , 2022, 43, 160-170.   | 0.4  | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 310 | Current Management of Glycemia in Children with Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2022, 386, 1155-1164.   | 27.0 | 14        |
| 311 | Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 461-470.  | 4.4  | 13        |
| 312 | Variability of Glycemic Outcomes and Insulin Requirements Throughout the Menstrual Cycle: A Qualitative Study on Women With Type 1 Diabetes Using an Open-Source Automated Insulin Delivery System. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210801. | 2.2  | 3         |
| 313 | A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 573-582.   | 4.4  | 9         |
| 314 | Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. <i>The Lancet Digital Health</i> , 2022, 4, e245-e255.   | 12.3 | 33        |
| 315 | Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States. <i>Clinical Diabetes</i> , 2022, 40, 413-424.   | 2.2  | 2         |
| 316 | Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114280.  | 13.7 | 32        |
| 317 | Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes. <i>Diabetologia</i> , 2022, 65, 1883-1894.  | 6.3  | 26        |
| 318 | Problems and methods of a closed-loop blood glucose control system construction. <i>Journal of Physics: Conference Series</i> , 2021, 2091, 012020.  | 0.4  | 0         |
| 319 | Assessment for Predictors of Rise in HbA1c During Extended Use of a Closed-Loop Control System. <i>Diabetes Technology and Therapeutics</i> , 2021, , .  | 4.4  | 0         |
| 320 | 7. Diabetes Technology: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S97-S112.  | 8.6  | 158       |
| 321 | 14. Children and Adolescents: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S208-S231.   | 8.6  | 104       |
| 322 | Closed-Loop Diabetes Minipatch Based on a Biosensor and an Electroosmotic Pump on Hollow Biodegradable Microneedles. <i>ACS Sensors</i> , 2022, 7, 1347-1360.  | 7.8  | 33        |
| 323 | Comparison of <sc>MiniMed 780G</sc> system performance in users aged younger and older than 15â€™years: Evidence from 12â€™870 realâ€™world users. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1370-1379.  | 4.4  | 73        |
| 324 | Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002633.  | 2.8  | 16        |
| 325 | Strengths and Challenges of Closed-Loop Insulin Delivery During Exercise in People With Type 1 Diabetes: Potential Future Directions. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1077-1084.   | 2.2  | 4         |
| 326 | Analysis of â€™Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States</i>. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210918.  | 2.2  | 0         |
| 327 | Accessibility and Openness to Diabetes Management Support With Mobile Phones: Survey Study of People With Type 1 Diabetes Using Advanced Diabetes Technologies. <i>JMIR Diabetes</i> , 2022, 7, e36140.  | 1.9  | 2         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 328 | Decision Support Systems and Closed-Loop. Diabetes Technology and Therapeutics, 2022, 24, S-58-S-75.  | 4.4  | 5         |
| 329 | Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2022, 24, S-107-S-128.  | 4.4  | 2         |
| 330 | Diabetes and Technology. Primary Care - Clinics in Office Practice, 2022, , .   | 1.6  | 1         |
| 331 | Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial. Journal of Diabetes Science and Technology, 2022, , 193229682210893.   | 2.2  | 4         |
| 332 | Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.   | 2.2  | 2         |
| 333 | Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2x2 factorial randomized crossover trial. Nature Medicine, 2022, 28, 1269-1276.  | 30.7 | 20        |
| 334 | Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4. Diabetes Technology and Therapeutics, 2022, 24, 635-642. | 4.4  | 8         |
| 335 | Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry. Journal of Diabetes Science and Technology, 2023, 17, 1580-1589.   | 2.2  | 2         |
| 336 | Friend or Foe: a Narrative Review of the Impact of Diabetes Technology on Sleep. Current Diabetes Reports, 2022, 22, 283-290.   | 4.2  | 12        |
| 337 | Electrogenetics: Bridging synthetic biology and electronics to remotely control the behavior of mammalian designer cells. Current Opinion in Chemical Biology, 2022, 68, 102151.  | 6.1  | 7         |
| 338 | Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial. Diabetes Technology and Therapeutics, 2022, 24, 666-671.  | 4.4  | 8         |
| 339 | Multi-Task Disentangled Autoencoder for Time-Series Data in Glucose Dynamics. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 4702-4713.   | 6.3  | 3         |
| 341 | Adaptive and Individualized Artificial Pancreas for Precision Management of Type 1 Diabetes. , 2022, , 305-313.   |      | 2         |
| 342 | Safety and Performance of Continuous Glucose Monitoring: An Overview. Current Diabetes Reviews, 2022, 18, .   | 1.3  | 1         |
| 343 | Meal and Physical Activity Detection from Free-Living Data for Discovering Disturbance Patterns of Glucose Levels in People with Diabetes. BioMedInformatics, 2022, 2, 297-317.   | 2.0  | 6         |
| 344 | Exploring dynamical properties of a Type 1 diabetes model using sensitivity approaches. Mathematics and Computers in Simulation, 2022, 201, 324-342.  | 4.4  | 0         |
| 345 | Hybrid Closed-Loop Systems and Glycemic Outcomes in Children and Adults With Type 1 Diabetes: Real-World Evidence From a U.S.-Based Multicenter Collaborative. Diabetes Care, 2022, 45, e118-e119.  | 8.6  | 15        |
| 346 | Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 797-804.   | 4.4  | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 347 | Insulin Replacement Across the Menstrual Cycle in Women with Type 1 Diabetes: An In Silico Assessment of the Need for Ad Hoc Technology. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 832-841.  | 4.4 | 4         |
| 348 | Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions. <i>Frontiers in Endocrinology</i> , 0, 13, .   | 3.5 | 29        |
| 350 | Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 779-783.  | 4.4 | 20        |
| 351 | Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes. <i>Current Cardiology Reports</i> , 2022, 24, 1159-1167.  | 2.9 | 6         |
| 352 | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes. , 2022, 18, 27.  |     | 4         |
| 354 | Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 814-823.  | 4.4 | 22        |
| 355 | Closed-Loop Controlled Fluid Administration Systems: A Comprehensive Scoping Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 1168.   | 2.5 | 8         |
| 356 | Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes. <i>Diabetic Medicine</i> , 2022, 39, .   | 2.3 | 7         |
| 357 | A centennial review of discoveries and advances in diabetes: Children and youth. <i>Pediatric Diabetes</i> , 2022, 23, 926-943.  | 2.9 | 2         |
| 358 | Machine Learning Approach for Care Improvement of Children and Youth with Type 1 Diabetes Treated with Hybrid Closed-Loop System. <i>Electronics (Switzerland)</i> , 2022, 11, 2227.   | 3.1 | 1         |
| 359 | The Digital Twin in Medicine: A Key to the Future of Healthcare?. <i>Frontiers in Medicine</i> , 0, 9, .   | 2.6 | 31        |
| 360 | Development of the Extended Infusion Set and Its Mechanism of Action. <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 454-459.   | 2.2 | 4         |
| 361 | Risk factors, mortality trends, and cardiovascular diseases in people with Type 1 diabetes and controls in Sweden: An observational cohort study. <i>Lancet Regional Health - Europe</i> , The, 2022, 21, 100469.  | 5.6 | 4         |
| 362 | Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 363-371.   | 2.2 | 2         |
| 363 | American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.  | 2.1 | 146       |
| 364 | One-Year Real-World Study on Comparison among Different Continuous Subcutaneous Insulin Infusion Devices for the Management of Pediatric Patients with Type 1 Diabetes: The Supremacy of Hybrid Closed-Loop Systems. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10293. | 2.6 | 6         |
| 365 | Automated insulin delivery systems: from early research to routine care of type 1 diabetes. <i>Acta Diabetologica</i> , 2023, 60, 151-161.   | 2.5 | 22        |
| 366 | Assessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 892-897.   | 4.4 | 9         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 367 | Electrospun nanofiber-based glucose sensors for glucose detection. <i>Frontiers in Chemistry</i> , 0, 10, .  | 3.6  | 50        |
| 368 | Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed <sup>®</sup> , 780G advanced hybrid closed-loop system: A randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 191, 110045. | 2.8  | 9         |
| 369 | Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy. <i>JAMA Surgery</i> , 2022, 157, 950.   | 4.3  | 12        |
| 370 | On the Path toward Expanding Treatment Options for Diabetes. <i>New England Journal of Medicine</i> , 2022, 387, 935-936.  | 27.0 | 1         |
| 371 | Improving HbA1c levels with advanced hybrid closed-loop therapy. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 684-686.   | 11.4 | 0         |
| 372 | Benefits and warnings after one year of Minimed 780G hybrid closed loop pump treatment in type 1 diabetes adults. <i>Diabetes Epidemiology and Management</i> , 2022, 8, 100110.   | 0.8  | 1         |
| 373 | Artificial Intelligence Algorithms for Treatment of Diabetes. <i>Algorithms</i> , 2022, 15, 299.   | 2.1  | 10        |
| 374 | Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2022, 387, 882-893.   | 27.0 | 33        |
| 375 | Grand challenges in mathematical biology: Integrating multi-scale modeling and data. <i>Frontiers in Applied Mathematics and Statistics</i> , 0, 8, .  | 1.3  | 3         |
| 376 | A Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell-derived Islets. <i>Endocrine Reviews</i> , 2023, 44, 222-253.  | 20.1 | 13        |
| 377 | Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System. <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 372-379.  | 2.2  | 9         |
| 378 | Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. <i>Endocrine Reviews</i> , 2023, 44, 254-280.   | 20.1 | 94        |
| 379 | Open-Source Automated Insulin Delivery in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2022, 387, 869-881.  | 27.0 | 71        |
| 380 | Use of Patient-Reported Outcomes for Assessing Diabetes Outcomes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 781-793.  | 3.2  | 1         |
| 381 | Reprogramming: Evolving Path to Functional Surrogate $\beta$ -Cells. <i>Cells</i> , 2022, 11, 2813.  | 4.1  | 1         |
| 382 | Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2022, 387, 1161-1172.  | 27.0 | 64        |
| 383 | Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 30, 178-194.                                    | 4.4  | 5         |
| 384 | Variation of glucose time in range in type 1 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 0, , .  | 2.4  | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 385 | Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis. <i>Diabetes Care</i> , 2022, 45, 2636-2643.  | 8.6 | 12        |
| 386 | The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 726-736.          | 4.4 | 9         |
| 387 | Pathophysiology and management of hypoglycemia in diabetes. <i>Annals of the New York Academy of Sciences</i> , 2022, 1518, 25-46.  | 3.8 | 3         |
| 388 | A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 681-696.  | 4.4 | 15        |
| 389 | A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 697-711.  | 4.4 | 15        |
| 390 | Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 3058-3074. | 8.6 | 18        |
| 391 | Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. <i>Diabetologia</i> , 2023, 66, 3-22.       | 6.3 | 22        |
| 392 | From islet of Langerhans transplantation to the bioartificial pancreas. <i>Presse Medicale</i> , 2022, 51, 104139.  | 1.9 | 6         |
| 394 | Transdermal amperometric biosensors for continuous glucose monitoring in diabetes. <i>Talanta</i> , 2023, 253, 124033.  | 5.5 | 8         |
| 395 | What Is a Digital Twin? Experimental Design for a Data-Centric Machine Learning Perspective in Health. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13149.  | 4.1 | 9         |
| 396 | Efficacy of Control-IQ Technology in a General Endocrine Clinic. <i>Endocrine Practice</i> , 2023, 29, 29-32.   | 2.1 | 2         |
| 397 | Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review. <i>Endocrine Practice</i> , 2023, 29, 214-220.  | 2.1 | 6         |
| 398 | Sodium-glucose co-transporter-2 inhibitors in Type 1 Diabetes: A Scoping Review. <i>Hormone Research in Paediatrics</i> , 0, , .  | 1.8 | 0         |
| 399 | Severe hypoglycaemia while using a hybrid closed-loop insulin pump system: A reminder of the continued importance of patient education for pre-emptive hypoglycaemia mitigation. <i>Diabetic Medicine</i> , 2023, 40, .   | 2.3 | 2         |
| 400 | Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. <i>Current Cardiology Reports</i> , 2022, 24, 2043-2056.  | 2.9 | 9         |
| 401 | Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies. <i>Nature Reviews Endocrinology</i> , 2023, 19, 177-186.  | 9.6 | 5         |
| 402 | A Review on Newer Interventions for the Prevention of Diabetic Foot Disease. <i>Cureus</i> , 2022, , .  | 0.5 | 1         |
| 403 | KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2022, 102, S1-S127.   | 5.2 | 246       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 405 | From digital control to digital twins in medicine: A brief review and future perspectives. <i>Advances in Applied Mechanics</i> , 2023, , 323-368.   | 2.3 | 4         |
| 406 | Hybrid Closed-Loop Insulin Pump Technology Can Be Safely Used in the Inpatient Setting. <i>Endocrine Practice</i> , 2023, 29, 24-28.   | 2.1 | 2         |
| 407 | Closed-loop insulin delivery: update on the state of the field and emerging technologies. <i>Expert Review of Medical Devices</i> , 2022, 19, 859-875.   | 2.8 | 13        |
| 408 | Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial. <i>Diabetes Care</i> , 2023, 46, 165-172.   | 8.6 | 7         |
| 409 | The role of machine learning in advancing precision medicine with feedback control. <i>Cell Reports Physical Science</i> , 2022, 3, 101149.  | 5.6 | 5         |
| 410 | Endocrine Complications of Cystic Fibrosis. <i>Clinics in Chest Medicine</i> , 2022, 43, 773-789.  | 2.1 | 3         |
| 411 | Type 1 and other types of diabetes mellitus in the perioperative period. What the anaesthetist should know. <i>Journal of Clinical Anesthesia</i> , 2023, 84, 111012.  | 1.6 | 4         |
| 412 | Artificial pancreas systems: experiences from concept to commercialisation. <i>Expert Review of Medical Devices</i> , 2022, 19, 877-894.   | 2.8 | 3         |
| 413 | Adjusting Therapy Profiles When Switching to Ultra-Rapid Lispro in an Advanced Hybrid Closed-Loop System: An in Silico Study. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682211404.  | 2.2 | 2         |
| 414 | Open-source automated insulin delivery systems and formal healthcare: A qualitative study of challenges in the interaction between service-users with type 1 diabetes and healthcare professionals. <i>Chronic Illness</i> , 0, , 174239532211423.   | 1.5 | 0         |
| 415 | 14. Children and Adolescents: <i>Standards of Care in Diabetesâ€™2023</i>. <i>Diabetes Care</i> , 2023, 46, S230-S253.   | 8.6 | 66        |
| 416 | 7. Diabetes Technology: <i>Standards of Care in Diabetes</i>â€™<i>2023</i>. <i>Diabetes Care</i> , 2023, 46, S111-S127.  | 8.6 | 108       |
| 417 | <sc>ISPAD</sc> Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes. <i>Pediatric Diabetes</i> , 2022, 23, 1322-1340.  | 2.9 | 19        |
| 418 | <sc>ISPAD</sc> Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. <i>Pediatric Diabetes</i> , 2022, 23, 1406-1431.  | 2.9 | 44        |
| 419 | Impaired awareness of hypoglycaemia. <i>British Journal of Diabetes</i> , 2022, 22, S26-S31.   | 0.2 | 1         |
| 420 | 9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetesâ€™2023</i>. <i>Diabetes Care</i> , 2023, 46, S140-S157.  | 8.6 | 339       |
| 421 | Study protocol: a randomised controlled proof-of-concept real-world study â€™ does maximising time in range using hybrid closed loop insulin delivery and a low carbohydrate diet restore the glucagon response to hypoglycaemia in adults with type 1 diabetes?. <i>BMJ Open</i> , 2022, 12, e054958. | 1.9 | 1         |
| 422 | Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682211419.   | 2.2 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 423 | Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .  | 2.7  | 6         |
| 424 | Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 529-562.  | 3.6  | 21        |
| 425 | To sleep or not to sleep: An Italian Control-IQ-uestion. <i>Frontiers in Endocrinology</i> , 0, 13, .   | 3.5  | 2         |
| 426 | The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment. <i>Endocrinologia, Diabetes Y Nutrici n</i> , 2023, 70, 130-135.  | 0.3  | 1         |
| 427 | Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682211440.  | 2.2  | 2         |
| 428 | Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics. <i>Advanced Science</i> , 2023, 10, .   | 11.2 | 9         |
| 429 | Digital twin in healthcare: Recent updates and challenges. <i>Digital Health</i> , 2023, 9, 205520762211496.  | 1.8  | 31        |
| 430 | Glycaemic control and novel technology management strategies in pregestational diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 13, .  | 3.5  | 4         |
| 431 | Maximizing Glycemic Benefits of Using Faster Insulin Formulations in Type 1 Diabetes: In Silico Analysis Under Open- and Closed-Loop Conditions. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 219-230.   | 4.4  | 3         |
| 432 | Applying the use of shared medical appointments (SMAs) to improve continuous glucose monitor (CGM) use, glycemic control, and quality of life in marginalized youth with type 1 diabetes: Study protocol for a pilot prospective cohort study. <i>Contemporary Clinical Trials Communications</i> , 2023, 32, 101067. | 1.1  | 2         |
| 434 | <scp>CGM</scp> accuracy: Contrasting <scp>CE</scp> marking with the governmental controls of the <scp>USA</scp> (<scp>FDA</scp>) and Australia (<scp>TGA</scp>): A narrative review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 916-939.   | 4.4  | 4         |
| 435 | Continuous Subcutaneous Insulin Infusions: Closing the Loop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1019-1033.  | 3.6  | 2         |
| 436 | Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections. <i>Diabetes Care</i> , 2023, 46, 628-632.  | 8.6  | 7         |
| 437 | Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 27-41.  | 4.7  | 14        |
| 438 | The Advanced Diabetes Technologies for Reduction of the Frequency of Hypoglycemia and Minimizing the Occurrence of Severe Hypoglycemia in Children and Adolescents with Type 1 Diabetes. <i>Journal of Clinical Medicine</i> , 2023, 12, 781.   | 2.4  | 6         |
| 439 | One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .   | 3.5  | 12        |
| 440 | Co-designing opportunities for Human-Centred Machine Learning in supporting Type 1 diabetes decision-making. <i>International Journal of Human Computer Studies</i> , 2023, 173, 103003.  | 5.6  | 2         |
| 441 | Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 287-292.   | 4.4  | 3         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 442 | Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 242-249.   | 4.4 | 2         |
| 443 | A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. <i>Diabetes Therapy</i> , 2023, 14, 839-855.  | 2.5 | 10        |
| 444 | Switching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110627. | 2.8 | 5         |
| 445 | Review of point-of-care platforms for diabetes: (2) medications and devices. <i>Sensors and Actuators Reports</i> , 2023, 5, 100150.   | 4.4 | 0         |
| 446 | A meta-learning approach to personalized blood glucose prediction in type 1 diabetes. <i>Control Engineering Practice</i> , 2023, 135, 105498.   | 5.5 | 4         |
| 447 | Expert Guidance on Off-Label Use of Hybrid Closed-Loop Therapy in Pregnancies Complicated by Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 363-373.  | 4.4 | 9         |
| 448 | Interest in hybrid closed loop is high across the socioeconomic spectrum despite current inequalities in provision in a large <sc>UK</sc> diabetes centre. <i>Diabetic Medicine</i> , 2023, 40, .  | 2.3 | 1         |
| 449 | The Artificial Pancreas and Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1614-1623.   | 3.6 | 9         |
| 450 | One-year real-world performance of the <sc>DBLG1</sc> closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1607-1613.   | 4.4 | 11        |
| 451 | Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 302-314.   | 4.4 | 11        |
| 452 | Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 250-259.  | 4.4 | 7         |
| 453 | Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. <i>Diabetes Care</i> , 2023, 46, 742-750.  | 8.6 | 13        |
| 454 | Closed-Loop and Artificial Intelligence-Based Decision Support Systems. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, S-70-S-89.   | 4.4 | 2         |
| 455 | Diabetes Technology and Therapy in the Pediatric Age Group. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, S-118-S-145.   | 4.4 | 0         |
| 456 | Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review. <i>European Journal of Pediatrics</i> , 2023, 182, 1949-1963.   | 2.7 | 4         |
| 457 | An artificial pancreas system in android phones: A dual app architecture. <i>Pervasive and Mobile Computing</i> , 2023, 91, 101767.  | 3.3 | 0         |
| 458 | Interruption of CGM: Frequency and Adverse Consequences. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682311565.   | 2.2 | 1         |
| 459 | School Nurse Confidence with Diabetes Devices in Relation to Diabetes Knowledge and Prior Training: A Study of Convergent Validity. <i>Pediatric Diabetes</i> , 2023, 2023, 1-7.   | 2.9 | 1         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 460 | Healthcare systems. , 2023, , 1-35.  |      | 3         |
| 461 | Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 0, , .   | 2.4  | 0         |
| 462 | Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 2023, 18, 131-142.   | 2.4  | 0         |
| 463 | Comparisons of School-Day Glycemia in Different Settings for Children with Type 1 Diabetes Using Continuous Glucose Monitoring. Pediatric Diabetes, 2023, 2023, 1-11.  | 2.9  | 0         |
| 464 | The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment. EndocrinologÅa Diabetes Y NutriciÅ³n (English Ed ), 2023, 70, 130-135.     | 0.2  | 1         |
| 465 | Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. New England Journal of Medicine, 2023, 388, 991-1001.  | 27.0 | 40        |
| 466 | Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023. Life, 2023, 13, 783.   | 2.4  | 2         |
| 467 | Hybrid Closed Loop Overcomes the Impact of Missed or Suboptimal Meal Boluses on Glucose Control in Children with Type 1 Diabetes Compared to Sensor-Augmented Pump Therapy. Diabetes Technology and Therapeutics, 2023, 25, 395-403. | 4.4  | 4         |
| 468 | Proof-of-concept Application of Continuous Glucose Monitoring Data Analytics to Identify Diabetes Glucotypes. Journal of the Endocrine Society, 2023, 7, .   | 0.2  | 0         |
| 469 | Real-world outcomes of continuous glucose monitoring in adults with diabetes mellitus attending an Irish tertiary hospital. Irish Journal of Medical Science, 0, , .   | 1.5  | 0         |
| 470 | Research progress in the application of time in range: more than a percentage. Chinese Medical Journal, 2023, 136, 522-527.  | 2.3  | 0         |
| 471 | Health-Care disparities in the use of diabetes technologies in the UK. , 2022, 1, 56.  |      | 0         |
| 472 | Technologies will not make diabetes disappear: how to integrate the concept of diabetes distress into care. Diabetes Epidemiology and Management, 2023, 11, 100140.  | 0.8  | 1         |
| 473 | Automated insulin delivery systems: Myths, legends and management of the Holy Grail. EndocrinologÅa Diabetes Y NutriciÅ³n (English Ed ), 2023, 70, 159-161.  | 0.2  | 0         |
| 474 | Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases. Journal of the Indian Institute of Science, 2023, 103, 205-230.   | 1.9  | 6         |
| 476 | Clinician Experiences With Hybrid Closed Loop Insulin Delivery Systems in Veterans With Type 1 Diabetes: Qualitative Study. JMIR Diabetes, 0, 8, e45241.   | 1.9  | 1         |
| 477 | Glycemic Risk Index Profiles and Predictors Among Diverse Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 0, , .  | 2.2  | 1         |
| 478 | The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes. Diabetes Care, 2023, 46, 1185-1190.  | 8.6  | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 479 | Patientsâ€™ opinions 10 years after receiving encapsulated porcine islet xenotransplantation without immunosuppression. <i>Xenotransplantation</i> , 2023, 30, .   | 2.8 | 3         |
| 480 | Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population. <i>Diabetes Care</i> , 2023, 46, 1218-1222.   | 8.6 | 7         |
| 481 | Effect of an Automated Advice Algorithm (CloudConnect) on Adolescent-Parent Diabetes-Specific Communication and Glycemic Management: A Randomized Trial. <i>Diabetes Therapy</i> , 0, , .  | 2.5 | 0         |
| 482 | School-Based Diabetes Care: A National Survey of U.S. Pediatric Diabetes Providers. <i>Pediatric Diabetes</i> , 2023, 2023, 1-10.  | 2.9 | 0         |
| 483 | Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 476-484.   | 4.4 | 2         |
| 484 | A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 329-342.                          | 4.4 | 19        |
| 487 | Patient-Reported Usefulness and Challenges in Using Hypoglycemia-Informing Features of Continuous Glucose Monitors to Manage Hypoglycemia. <i>Science of Diabetes Self-Management and Care</i> , 2023, 49, 229-238.                    | 1.6 | 2         |
| 488 | Diabetic Ketoacidosis in a Patient With Type I Diabetes Treated With a Closed-Loop Sensorâ€™Augmented Insulin Infusion System. <i>AACE Clinical Case Reports</i> , 2023, 9, 116-121.   | 1.1 | 2         |
| 489 | The Evolution of Diabetes Technology â€™ Options Toward Personalized Care. <i>Endocrine Practice</i> , 2023, , .   | 2.1 | 0         |
| 490 | Time in Range Goal is Achieved in a Unique Way. <i>Mayo Clinic Proceedings</i> , 2023, 98, 748-749.  | 3.0 | 0         |
| 491 | Cystic Fibrosisâ€™Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. <i>Diabetes</i> , 2023, 72, 677-689.   | 0.6 | 5         |
| 492 | Clinically-Similar Clusters of Daily CGM Profiles: Tracking the Progression of Glycemic Control Over Time. <i>Diabetes Technology and Therapeutics</i> , 0, , .  | 4.4 | 0         |
| 493 | A Randomized Crossover Trial to Compare Automated Insulin Delivery (the Artificial Pancreas) With Carbohydrate Counting or Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes. <i>Diabetes Care</i> , 2023, 46, 1372-1378. | 8.6 | 5         |
| 494 | Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2023, 29, 807-817.       | 0.9 | 3         |
| 495 | Editorial: Technologies for diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .   | 3.5 | 0         |
| 496 | Metabolic Outcomes in Pediatric Patients One-Year Post-Total Pancreatectomy with Islet Autotransplantation after Early Pump Initiation. <i>Journal of Clinical Medicine</i> , 2023, 12, 3319.  | 2.4 | 3         |
| 497 | Associations between clinical and psychosocial factors and HbA1c in adult insulin pump users with type 1 diabetes. <i>Acta Diabetologica</i> , 2023, 60, 1089-1097.  | 2.5 | 1         |
| 498 | Time Spent in Hypoglycemia According to Age and Time of Day: Observations During Closed-Loop Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 485-491.  | 4.4 | 2         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 499 | Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682311763.                                       | 2.2  | 0         |
| 500 | Glycemic Outcomes During Early Use of the MiniMed <sup>®</sup> , <sup>®</sup> 780G Advanced Hybrid Closed-Loop System with Guardian <sup>®</sup> , <sup>®</sup> 4 Sensor. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 652-658.                   | 4.4  | 8         |
| 501 | Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1 Diabetes in a Real-World Setting. <i>Pediatric Diabetes</i> , 2023, 2023, 1-10.   | 2.9  | 0         |
| 502 | Automated insulin delivery among adults with type 1 diabetes for up to 20 years: a real-world, multicentre study. <i>Internal Medicine Journal</i> , 2024, 54, 121-128.  | 0.8  | 2         |
| 503 | Insulin Delivery: An Evolution in the Technology. , 2023, , 1141-1158.   |      | 0         |
| 504 | Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review. <i>European Journal of Cell Biology</i> , 2023, 102, 151329.   | 3.6  | 2         |
| 505 | Real-World User and Clinician Perspective and Experience with MiniMed <sup>®</sup> , <sup>®</sup> 780G Advanced Hybrid Closed Loop System. <i>Diabetes Therapy</i> , 2023, 14, 1319-1330.  | 2.5  | 3         |
| 506 | The role of technology in the care of diabetes mellitus in pregnancy: an expert review. <i>AJOG Global Reports</i> , 2023, 3, 100245.  | 1.0  | 2         |
| 507 | Automatic Control in Systems Biology. <i>Springer Handbooks</i> , 2023, , 1189-1208.   | 0.6  | 0         |
| 508 | Closing the loop on adrenal health, dysfunction, and disease. <i>Science Translational Medicine</i> , 2023, 15, .  | 12.4 | 0         |
| 509 | “You have to use everything and come to some equilibrium”: a qualitative study on hypoglycemia self-management in users of continuous glucose monitor with diverse hypoglycemia experiences. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003415. | 2.8  | 5         |
| 511 | Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. <i>Diabetes Care</i> , 2023, 46, 1112-1123.  | 8.6  | 5         |
| 512 | Practical Aspects and Exercise Safety Benefits of Automated Insulin Delivery Systems in Type 1 Diabetes. <i>Diabetes Spectrum</i> , 2023, 36, 127-136.   | 1.0  | 7         |
| 513 | Current Trends and Strategies for Exercise in Diabetes. <i>Diabetes Spectrum</i> , 2023, 36, 100-103.  | 1.0  | 0         |
| 514 | Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world. <i>Diabetes Research and Clinical Practice</i> , 2023, 201, 110730.          | 2.8  | 1         |
| 515 | Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Clinical Chemistry</i> , 2023, 69, 808-868.  | 3.2  | 10        |
| 516 | Lifestyle and Nutrition Therapy. <i>Contemporary Cardiology</i> , 2023, , 785-823.   | 0.1  | 0         |
| 517 | One Size Fits All Versus Individualized Medicine in Type 1 Diabetes Management. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, S-42-S-47.   | 4.4  | 2         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 518 | Under-Representation of Diverse Populations and Glycemic Outcomes in Major Clinical Trials of Automated Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 752-754.   | 4.4  | 2         |
| 519 | A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 612-621. | 4.4  | 6         |
| 520 | Preparing for the demands of the future of work: Engineering organizations, creativity, and innovation. , 2023, , 315-327.   |      | 0         |
| 521 | Quantifying Insulin-Mediated and Non-Insulin-Mediated Changes in Glucose Dynamics during Resistance Exercise in Type 1 Diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 0, , .   | 3.5  | 0         |
| 522 | The Advanced Hybrid Closed Loop Improves Glycemia Risk Index, Continuous Glucose Monitoring Index, and Time in Range in Children with Type 1 Diabetes: Real-World Data from a Single Center Study. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 689-696.                    | 4.4  | 2         |
| 523 | Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia. <i>Journal of Diabetes Science and Technology</i> , 0, , .  | 2.2  | 0         |
| 524 | First Generation of a Modular Interoperable Closed-Loop System for Automated Insulin Delivery in Patients With Type 1 Diabetes: Lessons From Trials and Real-Life Data. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1433-1439.                                       | 2.2  | 2         |
| 525 | Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. <i>Diabetes Care</i> , 2023, 46, 1646-1651.  | 8.6  | 1         |
| 526 | Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Diabetes Care</i> , 2023, 46, e151-e199.   | 8.6  | 12        |
| 527 | A simple modeling framework for prediction in the human glucose-insulin system. <i>Chaos</i> , 2023, 33, .   | 2.5  | 3         |
| 529 | New therapies towards a better glycemic control in youths with type 1 diabetes. <i>Pharmacological Research</i> , 2023, 195, 106882.   | 7.1  | 0         |
| 530 | Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial. <i>The Lancet Digital Health</i> , 2023, 5, e607-e617.  | 12.3 | 2         |
| 531 | Model predictive control to account for prolonged changes in insulin requirements following exercise in type 1 diabetes. <i>Journal of Process Control</i> , 2023, 129, 103042.  | 3.3  | 1         |
| 532 | Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US. , 2023, 1, 210-218.  |      | 0         |
| 534 | An mHealth Text Messaging Program Providing Symptom Detection Training and Psychoeducation to Improve Hypoglycemia Self-Management: Intervention Development Study. <i>JMIR Formative Research</i> , 0, 7, e50374.   | 1.4  | 0         |
| 535 | Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study. <i>Diabetes Care</i> , 2023, 46, 1958-1964.   | 8.6  | 3         |
| 536 | Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13139.  | 4.1  | 2         |
| 537 | Optimizing Glycemic Outcomes for Minoritized and Medically Underserved Adults Living with Type 1 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2024, 53, 67-80.   | 3.2  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 538 | User experiences during the transition to calibration-free sensors with remote monitoring while using automated insulin delivery -A qualitative study. <i>Frontiers in Endocrinology</i> , 0, 14, .   | 3.5 | 0         |
| 539 | Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes. <i>Clinical Diabetes</i> , 0, , .   | 2.2 | 1         |
| 541 | Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 782-789.   | 4.4 | 2         |
| 542 | Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003485.   | 2.8 | 0         |
| 543 | Communication protocols integrating wearables, ingestibles, and implantables for closed-loop therapies. , 2023, 1, 100092.  |     | 5         |
| 544 | Glucose Rate-of-Change and Insulin-on-Board Jointly Weighted Zone Model Predictive Control. <i>IEEE Transactions on Control Systems Technology</i> , 2023, 31, 2261-2274.   | 5.2 | 0         |
| 545 | Dual hormone fully closed loop in type 1 diabetes: a randomised trial in the Netherlands â€“ study protocol. <i>BMJ Open</i> , 2023, 13, e074984.   | 1.9 | 1         |
| 546 | Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. <i>Communications Medicine</i> , 2023, 3, .  | 4.2 | 1         |
| 547 | Evaluating a systematic intensive therapy using continuous glucose monitoring and intermittent scanning glucose monitoring in clinical diabetes care: a protocol for a multi-center randomized clinical trial. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 4, . | 0.8 | 0         |
| 548 | Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 2295-2310.  | 2.4 | 2         |
| 549 | Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. <i>Journal of Diabetes Science and Technology</i> , 0, , .   | 2.2 | 0         |
| 550 | Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .  | 2.7 | 2         |
| 551 | Evidence from clinical trials on high-risk medical devices in children: a scoping review. <i>Pediatric Research</i> , 2024, 95, 615-624.  | 2.3 | 2         |
| 552 | Assessment of Meal Anticipation for Improving Fully Automated Insulin Delivery in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2023, 46, 1652-1658.  | 8.6 | 2         |
| 553 | Glucose control during Ramadan in a pediatric cohort with type 1 diabetes on MiniMed standard and advanced hybrid closed-loop systems: A pilot study. <i>Diabetes Research and Clinical Practice</i> , 2023, 203, 110867.   | 2.8 | 2         |
| 554 | Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. <i>Diabetes Care</i> , 2023, 46, 1831-1838.   | 8.6 | 3         |
| 555 | Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 883-892.   | 4.4 | 2         |
| 556 | Reverse iontophoresis generated by porous microneedles produces an electroosmotic flow for glucose determination. <i>Talanta</i> , 2024, 267, 125156.   | 5.5 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 557 | Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2023, 46, 2180-2187.                                      | 8.6 | 2         |
| 558 | Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 78-84.   | 4.4 | 0         |
| 560 | Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care. <i>Diabetes Technology and Therapeutics</i> , 2023, 25, 877-882.  | 4.4 | 1         |
| 561 | A multivariate physiological model of vagus nerve signalling during metabolic challenges in anaesthetised rats for diabetes treatment. <i>Journal of Neural Engineering</i> , 2023, 20, 056033.   | 3.5 | 0         |
| 562 | Efficacy of the MiniMed, 670G hybrid closed loop system in managing postprandial glucose excursion with high protein high fat foods in children and adolescents under free-living conditions. , 0, .  |     | 2         |
| 563 | Simulation-driven optimization of insulin therapy profiles in a commercial hybrid closed-loop system. <i>Computer Methods and Programs in Biomedicine</i> , 2023, 242, 107830.  | 4.7 | 0         |
| 564 | Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. <i>Diabetes Technology and Therapeutics</i> , 2024, 26, 24-32. | 4.4 | 1         |
| 565 | Real-World Glycemic Improvements with Hybrid Closed Loop Pumps in Youth with Type 1 Diabetes. <i>Pediatric Diabetes</i> , 2023, 2023, 1-7.  | 2.9 | 0         |
| 566 | Combining Glucose Monitoring and Insulin Infusion in an Integrated Device: A Narrative Review of Challenges and Proposed Solutions. <i>Journal of Diabetes Science and Technology</i> , 0, , .  | 2.2 | 0         |
| 567 | 2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps. <i>Journal of Korean Diabetes</i> , 2023, 24, 141-147.   | 0.3 | 0         |
| 568 | A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes. <i>Diabetes Care</i> , 2023, 46, 2258-2266.   | 8.6 | 1         |
| 569 | Safety and performance of a hybrid closed-loop insulin delivery system with carbohydrate suggestion in adults with type 1 diabetes prone to hypoglycemia. <i>Diabetes Research and Clinical Practice</i> , 2023, 205, 110956.   | 2.8 | 0         |
| 571 | Patient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: a follow-up study. <i>EndocrinologÃa Diabetes Y NutriciÃ3n (English Ed )</i> , 2023, , .  | 0.2 | 0         |
| 572 | Analysis of â€œHybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetesâ€•. <i>Journal of Diabetes Science and Technology</i> , 0, , .   | 2.2 | 0         |
| 573 | Closed loop insulin deliveryâ€œOpportunities and limitations. <i>Journal of Diabetes</i> , 2023, 15, 1103-1106.   | 1.8 | 0         |
| 574 | The Hybrid Closed-Loop System Tandem t:slim X2â„¢ with Control-IQ Technology: Expert Recommendations for Better Management and Optimization. <i>Diabetes Therapy</i> , 0, , .   | 2.5 | 0         |
| 576 | Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosisâ€œRelated Diabetes. <i>Diabetes Care</i> , 0, , .  | 8.6 | 0         |
| 577 | Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: An ageâ€œperiodâ€œcohort analysis. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 602-610.  | 4.4 | 1         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 578 | Mitigating iftar-related glycemc excursions in adolescents and young adults with type 1 diabetes on MiniMedâ„¢ 780G advanced hybrid closed loop system: a randomized clinical trial for adjunctive oral vildagliptin therapy during Ramadan fasting. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, . | 2.7  | 0         |
| 579 | Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system. <i>Diabetes Research and Clinical Practice</i> , 2023, 206, 111011.   | 2.8  | 0         |
| 580 | Faults And Fault Tolerance In Automated Insulin Delivery Systems With An Emphasis On Human-In-The-Loop. <i>IFAC-PapersOnLine</i> , 2023, 56, 11503-11514.  | 0.9  | 0         |
| 581 | Should people with type 2 diabetes treated by multiple daily insulin injections with home health care support be switched to hybrid closedâ€loop? The <sc>CLOSE AP</sc>+ randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 622-630.   | 4.4  | 0         |
| 582 | Effects of hybrid closedâ€loop system on glycemc control and psychological aspects in persons with typeâ€1 diabetes treated with sensorâ€augmented pump: A prospective singleâ€center observational study. <i>Journal of Diabetes Investigation</i> , 0, , .   | 2.4  | 0         |
| 583 | Artificial intelligence and machine learning for improving glycemc control in diabetes: best practices, pitfalls and opportunities. <i>IEEE Reviews in Biomedical Engineering</i> , 2023, , 1-19.  | 18.0 | 1         |
| 584 | Characteristics associated with having a hemoglobin A1câ€7â€ (â€53â€mmol/mol) among adults with type 1 diabetes using an automated insulin delivery system. <i>Diabetes Research and Clinical Practice</i> , 2023, 206, 111006.  | 2.8  | 1         |
| 585 | A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. <i>Diabetes Care</i> , 2024, 47, 216-224.  | 8.6  | 2         |
| 586 | Impact of hybrid closedâ€loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1105-1109.   | 4.4  | 0         |
| 587 | A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus. <i>Nutrients</i> , 2023, 15, 4897.  | 4.1  | 2         |
| 588 | Digital Technology for Diabetes. <i>New England Journal of Medicine</i> , 2023, 389, 2076-2086.  | 27.0 | 3         |
| 589 | Basic carbohydrate counting and glycemia in young people with type 1 diabetes in India: A randomized controlled trial. <i>Nutrition</i> , 2024, 119, 112318.   | 2.4  | 0         |
| 590 | Impact of pancreas transplantation alone on kidney function: A multicenter clinical cohort study. <i>Clinical Transplantation</i> , 0, , .   | 1.6  | 0         |
| 592 | 7. Diabetes Technology: <i>Standards of Care in Diabetesâ€2024</i>. <i>Diabetes Care</i> , 2024, 47, S126-S144.  | 8.6  | 4         |
| 593 | 9. Pharmacologic Approaches to Glycemc Treatment: <i>Standards of Care in Diabetesâ€2024</i>. <i>Diabetes Care</i> , 2024, 47, S158-S178.  | 8.6  | 11        |
| 594 | 14. Children and Adolescents: <i>Standards of Care in Diabetesâ€2024</i>. <i>Diabetes Care</i> , 2024, 47, S258-S281.  | 8.6  | 3         |
| 595 | Addressing disparities in technology use among patients with type 1 diabetes: a review. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2024, 31, 14-21.   | 2.3  | 1         |
| 596 | Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems. <i>Diabetes Technology and Therapeutics</i> , 0, , .  | 4.4  | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 597 | Glycaemic outcomes in adults with type 1 diabetes transitioning towards advanced automated insulin delivery systems – a real-world analysis at a Swiss tertiary centre. <i>Swiss Medical Weekly</i> , 2023, 153, 3501.    | 1.6 | 0         |
| 598 | (Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise. <i>Diabetes Technology and Therapeutics</i> , 0, , .  | 4.4 | 1         |
| 599 | Care of Young Children With Diabetes in the Childcare and Community Setting: A Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2023, 46, 2102-2111.  | 8.6 | 2         |
| 602 | Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care. , 2024, 15, 18-23.   |     | 0         |
| 604 | Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems. <i>Diabetes Technology and Therapeutics</i> , 2024, 26, 263-275.                 | 4.4 | 3         |
| 605 | Polymers for implantable bioartificial pancreas. , 2024, , 337-375.   |     | 0         |
| 606 | New advances in type 1 diabetes. <i>BMJ, The</i> , 0, , e075681.  | 6.0 | 0         |
| 607 | Model Predictive Control (MPC) of an artificial pancreas with data-driven learning of multi-step-ahead blood glucose predictors. <i>Control Engineering Practice</i> , 2024, 144, 105810.                                 | 5.5 | 0         |
| 608 | Impact of 6-months of an advanced hybrid closed-loop system on sleep and psychosocial outcomes in youth with type 1 diabetes and their parents. <i>Diabetes Research and Clinical Practice</i> , 2024, 207, 111087.       | 2.8 | 0         |
| 611 | Short: Basal-Adjust: Trend Prediction Alerts and Adjusted Basal Rates for Hyperglycemia Prevention. , 2023, , .   |     | 0         |
| 612 | Postprandial glucose management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1555-1566.       | 4.4 | 0         |
| 613 | Treatment and prevention of type 1 diabetes in the 21st century. , 2023, , 145-167.   |     | 0         |
| 614 | Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology. <i>Diabetes Research and Clinical Practice</i> , 2024, 208, 111114. | 2.8 | 0         |
| 615 | Current and Emerging Technologies for the Diagnosis and Treatment of Diabetes Mellitus. <i>Current Emergency and Hospital Medicine Reports</i> , 2024, 12, 1-12.  | 1.5 | 0         |
| 616 | Effects of Macronutrient Intake and Number of Meals on Glycemic Outcomes Over 1 Year in Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 0, , .  | 4.4 | 0         |
| 617 | Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm. <i>Diabetes Technology and Therapeutics</i> , 0, , .   | 4.4 | 0         |
| 618 | Model Predictive Control with Dynamic Positive Input Extension for Artificial Pancreas Applications. , 2023, , .  |     | 0         |
| 619 | Impulsive Model Predictive Control in Type 1 Diabetes Mellitus Applications. , 2023, , .  |     | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 620 | Assessment of the Impact of Subcutaneous Catheter Change on Glucose Control in Patients with Type 1 Diabetes Treated by Insulin Pump in Open- and Closed-Loop Modes. Diabetes Technology and Therapeutics, 0, , .   | 4.4  | 0         |
| 622 | The Digital Twin for Personalised Medicine: A Systematic Review. , 2024, 6, 28-43.  |      | 0         |
| 623 | The Myth of MARD (<u>M</u>ean <u>A</u>bsolute <u>R</u>elative <u>D</u>ifference): Limitations of MARD in the Clinical Assessment of Continuous Glucose Monitoring Data. Diabetes Technology and Therapeutics, 2024, 26, 38-44.  | 4.4  | 0         |
| 624 | Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology and Therapeutics, 2024, 26, 53-65.  | 4.4  | 0         |
| 625 | Real-World Evidence of Omnipod<sup>Â®</sup> 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology and Therapeutics, 0, , .   | 4.4  | 0         |
| 626 | Development and Future of Automated Insulin Delivery (AID) Systems. Diabetes Technology and Therapeutics, 2024, 26, 1-6.  | 4.4  | 0         |
| 627 | Early Real-World Performance of the MiniMedâ„¢ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technology and Therapeutics, 2024, 26, 24-31.  | 4.4  | 0         |
| 628 | Wireless Battery-free and Fully Implantable Organ Interfaces. Chemical Reviews, 2024, 124, 2205-2280.   | 47.7 | 0         |
| 629 | Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the â€˜CLOSE ITâ€™™ (Closed Loop Open Source In Type 1 diabetes) trial. BMJ Open, 2024, 14, e078171. | 1.9  | 0         |
| 630 | Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force. Journal of Cystic Fibrosis, 2024, , .  | 0.7  | 0         |
| 631 | Randomized Trial of Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy in Pregnancy. Diabetes Technology and Therapeutics, 0, , .   | 4.4  | 0         |
| 632 | Carbohydrate counting knowledge and ambulatory glucose profile in persons living with type 1 diabetes. Diabetes Research and Clinical Practice, 2024, 210, 111592.  | 2.8  | 0         |
| 633 | Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands. The Lancet Digital Health, 2024, 6, e272-e280.  | 12.3 | 0         |
| 634 | Closed-Loop Control, Artificial Intelligenceâ€‘Based Decision-Support Systems, and Data Science. Diabetes Technology and Therapeutics, 2024, 26, S-68-S-89.   | 4.4  | 0         |
| 635 | Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2024, 26, S-117-S-140.  | 4.4  | 0         |
| 636 | Hybrid Closed Loop Systems Improve Glycemic Control and Quality of Life in Historically Minoritized Youth with Diabetes. Diabetes Technology and Therapeutics, 2024, 26, 167-175.   | 4.4  | 0         |
| 637 | Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed IOoP In children and youth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial. Journal of Diabetes and Metabolic Disorders, 0, , .                         | 1.9  | 0         |
| 638 | Development of Machine Learning Models for the Identification of Elevated Ketone Bodies During Hyperglycemia in Patients with Type 1 Diabetes. Diabetes Technology and Therapeutics, 0, , .   | 4.4  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 639 | Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability. <i>Frontiers in Endocrinology</i> , 0, 15, .   | 3.5 | 0         |
| 640 | QSAR Studies of Sodium/Glucose Co-Transporter 2 Inhibitors as Potent Anti-Diabetic Drug Agents. <i>Theoretical Foundations of Chemical Engineering</i> , 2023, 57, S51-S56.   | 0.7 | 0         |
| 641 | Insulinâ€™s Legacy: A Century of Breakthroughs and Innovation. <i>Cardiology in Review</i> , 0, , .   | 1.4 | 0         |
| 643 | Cost-Effectiveness of Closed-Loop Automated Insulin Delivery Using the Cambridge Hybrid Algorithm in Children and Adolescents with Type 1 Diabetes: Results from a Multicenter 6-Month Randomized Trial. <i>Journal of Diabetes Science and Technology</i> , 0, , . | 2.2 | 0         |